Core Insights - Bio-Techne Corporation (TECH) announced advancements in its spatial biology portfolio, specifically the RNAscope ISH technology and Lunaphore COMET, which are expected to enhance clinical utility workflows for lymphoid malignancies and B-cell clonality [1][8] - The company will showcase these innovations at the National Society for Histotechnology (NSH) Convention from September 26-30 in Long Beach, CA [1][8] Company Performance - Following the announcement on September 26, Bio-Techne shares increased by 2.7%, closing at $51.85 [2][8] - The company has a market capitalization of $8.07 billion and an earnings yield of 3.9%, which is significantly better than the industry's -21.1% [3] - Over the trailing four quarters, Bio-Techne delivered an average earnings surprise of 9.2% [3] Product Innovations - RNAscope technology allows for the detection of clinically relevant biomarkers within routine anatomic pathology workflows, while COMET provides automated, high-throughput analysis of RNA and protein biomarkers [4] - Scientific studies presented at the NSH highlighted the use of RNAscope for assessing B-cell clonality and COMET for spatial profiling of lymphoid malignancies [5][10] Market Trends - The spatial biology market is projected to grow from $1.64 billion in 2024 to $1.79 billion in 2025, with expectations to reach $2.88 billion by 2030, reflecting a CAGR of 9.85% [11] Recent Developments - In August, Bio-Techne agreed to sell its Exosome Diagnostics business to Mdxhealth SA while retaining rights to the exosome technology for future kit development [12]

Core Insights - Bio-Techne Corporation announced advancements in its spatial biology portfolio, specifically for RNAscope™ ISH technology and Lunaphore COMET™, which enhance the detection of RNA and protein biomarkers on the same tissue section [1][7]. Product Advancements - RNAscope™ technology allows pathologists to detect clinically relevant biomarkers within routine anatomic pathology workflows, while COMET™ provides fully automated, high-throughput hyperplex analysis of RNA and protein biomarkers, facilitating spatial multiomic workflows [2][7]. - The integration of these technologies into diagnostic workflows is being explored, particularly for assessing B-cell clonality and spatial profiling of lymphoid malignancies [3][7]. Event Participation - Bio-Techne will showcase its innovations at the National Society of Histotechnology (NSH) Convention from September 26–30 in Long Beach, CA, with presentations highlighting the advantages of RNAscope™ and its applications in clinical diagnostics [4][8]. Research Highlights - Studies presented include the use of RNAscope™ for assessing B-cell clonality and the application of COMET™ for spatial profiling of lymphoid malignancies, demonstrating the potential clinical utility of these technologies [3][8]. Company Overview - Bio-Techne Corporation is a global life sciences company that generated over $1.2 billion in net sales in fiscal 2025 and employs approximately 3,100 people worldwide, providing innovative tools and reagents for research and clinical diagnostics [9].

Group 1 - Mairs & Power Balanced Fund reported a return of 2.66% in the first half of 2025, underperforming benchmark indexes which rose 5.43% and 5.67% respectively [1] - The fund's performance was impacted by external factors such as tariff uncertainty, conflicts in the Middle East, and rising national debt [1] - The fund experienced a recovery, rising 25% from its low at the beginning of the quarter [1] Group 2 - Bio-Techne Corporation (NASDAQ:TECH) has a market capitalization of $8.239 billion and focuses on life science reagents, instruments, and services [2] - The stock of Bio-Techne Corporation saw a one-month return of -5.87% and a 52-week decline of 29.39%, closing at $52.92 per share on September 23, 2025 [2] - The company underperformed due to uncertainty in the funding environment, influenced by federal funding cuts and a weak venture capital landscape [3] Group 3 - Bio-Techne Corporation generated $317 million in revenues in the fiscal fourth quarter of 2025, reflecting a 3% year-over-year increase on an organic basis and a 4% increase on a reported basis [4] - The company is not among the 30 most popular stocks among hedge funds, with 37 hedge fund portfolios holding its stock at the end of the second quarter, up from 34 in the previous quarter [4] - Despite acknowledging Bio-Techne's potential, the company believes certain AI stocks present greater upside potential and lower downside risk [4]

Company Overview - Bio-Techne Corporation (TECH) is headquartered in Minneapolis, Minnesota, and specializes in developing, manufacturing, and selling life science reagents, instruments, and services for research, diagnostics, and bioprocessing markets, with a market cap of $8.3 billion [1] - The company focuses on proteins, cytokines, growth factors, immunoassays, and small molecules, positioning itself as a significant player in the biotechnology industry [1] Market Position - TECH is classified as a mid-cap stock, with a market cap exceeding $2 billion, highlighting its size, influence, and dominance within the biotechnology sector [2] - The company is committed to innovation, strategic acquisitions, and has a global presence, which positions it for continued success and growth opportunities both domestically and internationally [2] Stock Performance - Despite its strengths, TECH's stock has decreased by 34.5% from its 52-week high of $80.80, reached on November 6, 2024 [3] - Over the past three months, TECH stock gained 7.3%, underperforming the Dow Jones Industrials Average, which gained 8.7% during the same period [3] - Year-to-date, shares of TECH have dipped 26.5%, and over the past 52 weeks, they have fallen 31.5%, significantly underperforming the Dow Jones Industrials Average's YTD gains of 8.8% and 9.9% returns over the last year [4] Recent Financial Results - On August 6, TECH reported its Q4 results, with an adjusted EPS of $0.53, surpassing Wall Street expectations of $0.50, and revenue of $317 million, exceeding forecasts of $315.4 million [5] - In comparison, Adaptive Biotechnologies Corporation (ADPT) has shown significant resilience, with YTD gains of 132.4% and 227% returns over the past 52 weeks, indicating a competitive challenge for TECH [5]

Core Insights - Bio-Techne Corporation emphasizes its commitment to sustainability and human health through its 2025 Corporate Sustainability Report, highlighting the intrinsic connection between human health and environmental protection [2][4] - The company aims to achieve a 40% reduction in Scope 1 and 2 greenhouse gas emissions by transitioning to 100% renewable electricity at its Minneapolis headquarters [6] - Bio-Techne plans to set greenhouse gas reduction targets for Scope 1, 2, and 3, with validation submission to the Science Based Targets Initiative (SBTi) in 2026 [6] Sustainability Initiatives - The sustainability initiatives are designed to drive innovation across Bio-Techne's life sciences portfolio, focusing on efficiency and resource-conscious design in areas such as cell therapy workflows and precision diagnostics [3] - Enhanced governance measures include new Board oversight of artificial intelligence and the completion of double materiality and climate assessments to guide sustainability priorities [6] Financial Performance - Bio-Techne generated over $1.2 billion in net sales in fiscal 2025, showcasing its strong market position and financial health [5] - The company employs approximately 3,100 individuals worldwide, indicating a robust operational scale [5] Commitment to Employees and Communities - The company invests in culture and career development, providing learning opportunities aligned with its EPIC values: Empowerment, Passion, Innovation, and Collaboration [6] - Bio-Techne's leadership emphasizes the importance of diverse perspectives in driving innovation and creating lasting impact within communities [4]

Core Insights - The Brown Capital Management Small Company Fund experienced an 8.59% return in Q2 2025, underperforming the Russell 2000® Growth index which returned 11.97% [1] - The underperformance was noted to occur in the last few weeks of the quarter [1] Company Highlights - Bio-Techne Corporation (NASDAQ:TECH) is highlighted in the investor letter, with a market capitalization of $7.973 billion [2] - Bio-Techne's one-month return was -3.81%, and it experienced a significant decline of 31.43% over the past 52 weeks, closing at $51.26 per share on September 12, 2025 [2] - Bio-Techne Corporation was identified as a detractor to the fund's performance in Q2 2025 [3]

Group 1 - Bio-Techne stands out in the life science tools landscape due to its growth and margin profile [1] - The company trades at a more premium valuation multiple compared to its peers [1] - Understanding Bio-Techne's strategic positioning is crucial for investors, especially those new to the story [1]

Core Insights - Paramount, a Skydance Corporation, has appointed Dane Glasgow as Chief Product Officer, emphasizing its commitment to innovation in the entertainment sector [1][2][3] Company Overview - Paramount operates as a leading global media and entertainment company, structured into three segments: Studios, Direct-to-Consumer, and TV Media [4] - The company's portfolio includes renowned brands such as Paramount Pictures, CBS, Nickelodeon, and Showtime, among others [4] Leadership and Strategy - Glasgow will report directly to CEO David Ellison and is tasked with leading the product vision and strategy, focusing on digital platforms, immersive storytelling, and AI capabilities [2] - The appointment is seen as a strategic move to enhance Paramount's position in delivering consumer-focused media experiences [2][3] Executive Statements - CEO David Ellison highlighted Glasgow's extensive experience in scaling businesses and driving technological transformation as crucial for Paramount's growth [3] - Glasgow expressed enthusiasm about joining Paramount, emphasizing the opportunity to shape the future of entertainment through innovative technology [3]

Bio-Techne FY Conference Summary Company Overview - **Company**: Bio-Techne (NasdaqGS: TECH) - **Industry**: Life Science Tools Key Points Company Positioning and Growth Strategy - Bio-Techne is a leader in reagents for life science research, focusing on proteins, antibodies, and assays for diagnostics and therapeutics [4][6] - The company has invested heavily in automation of protein analytics, spatial biology, and cell therapy, which now account for approximately 45% of revenue, up from 30% pre-COVID [6][7] - 90% of Bio-Techne's business is recurring, primarily from consumables, which supports sustainable growth [7] Recent Financial Performance - The company reported a 3% growth in the most recent quarter, with notable performance in China (10% growth) and continued double-digit growth in large pharma [9][10] - Challenges included delays in shipping high-priced instruments due to geopolitical issues [9] Academic Market Exposure - Academic sales account for about 20% of total revenue, with U.S. academia contributing approximately 11-12% [13][14] - Despite funding constraints, consumables have remained flat, indicating resilience in the product portfolio [14][15] Market Dynamics in China - Positive sentiment in China suggests a gradual ramp-up in growth, with expectations of returning to double-digit growth in the long term [18][19] Biopharma Market Insights - Biopharma constitutes roughly 50% of revenue, with large pharma showing strong recovery and growth, while biotech funding has decreased significantly [20][21] - The uncertainty in biotech funding may impact future spending, but recent improvements in funding could signal a recovery [22] Cell Therapy Business - Bio-Techne is well-positioned in the cell therapy market, focusing on GMP proteins, with a significant increase in revenue from this segment [23][24] - The company has built a strong reputation for quality and has a competitive edge in the regen med space, which has greater market potential than CAR-T therapies [25][26] Core Reagents and Instrumentation - The core reagents business remains stable, with healthy competition in the antibody market [30][31] - The ProteinSimple platform has shown resilience, with growth driven by increased usage of consumables despite a downturn in new instrument placements [34][36] Spatial Biology and Competitive Position - Bio-Techne leads in spatial biology with RNAscope reagents and the new COMET instrument, which automates RNA and protein detection [39][41] - The company is positioned to capitalize on the growing demand for translational research tools [40] Strategic Divestiture - The recent divestiture of the Exosome Diagnostics business was driven by a misalignment with Bio-Techne's core capabilities and a lack of a clear path to profitability [43][45] Revenue Outlook and Market Conditions - The company anticipates low single-digit growth, managing costs and investments amid market uncertainties [47][50] - Optimism remains regarding recovery in key markets, with expectations that administrative-induced noise will settle down [51][53] Conclusion Bio-Techne is strategically positioned for growth in the life science tools industry, with a strong focus on automation, spatial biology, and cell therapy. Despite current market challenges, the company maintains a positive outlook for future performance driven by its recurring revenue model and innovative product offerings.

Core Insights - The company identifies three key end markets: pharmaceuticals (approximately 30% of revenue), smaller biotech (around 20%), and academia (also about 20%) [1] - The pharmaceutical sector is expected to experience a pipeline reshuffling due to the IRA legislation, with anticipated impacts continuing into 2024 but expected to stabilize by 2025 [1] - R&D funding is projected to be allocated more evenly across the portfolio, rather than being heavily focused on early-stage projects [1]